Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe

Ji-Young Park, Kyoung Ah Kim, Pil Whan Park, Jong Myung Ha

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The authors evaluated the effect of high-dose aspirin at a therapeutic dose, using chlorzoxazone as a probe for CYP2E1 enzyme activity. In a randomized, open-label, 2-way crossover study, 10 healthy men were treated 3 times daily for 6 days with 1 g aspirin or placebo. On day 7, 1 dose of 400 mg chlorzoxazone was administered orally. Plasma concentrations of chlorzoxazone and its metabolite, 6-hydroxychlorzoxazone, were measured. During the aspirin phase, the area under the time-concentration curve (AUC) and peak plasma concentration of chlorzoxazone were 95% (90% confidence interval [CI], 87%-103%) and 90% (90% CI, 80%-101%) of the values during the placebo phase, respectively. High-dose aspirin did not affect the oral clearance of chlorzoxazone significantly (90% CI, 98%-120%; P = .24). The AUC ratio and plasma concentration ratios of 6-hydroxychlorzoxazone/chlorzoxazone were not changed significantly by high-dose aspirin. High-dose aspirin at a therapeutic dose does not affect CYP2E1 activity in humans.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalJournal of Clinical Pharmacology
Volume46
Issue number1
DOIs
Publication statusPublished - 2006 Jan 1
Externally publishedYes

Fingerprint

Chlorzoxazone
Cytochrome P-450 CYP2E1
Aspirin
Healthy Volunteers
Confidence Intervals
Area Under Curve
Placebos
Human Activities
Cross-Over Studies
Enzymes
Therapeutics

Keywords

  • Aspirin
  • Chlorzoxazone, 6-hydroxychlorzoxazone
  • Cytochrome P450 2E1 (CYP2E1)
  • Drug interaction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe. / Park, Ji-Young; Kim, Kyoung Ah; Park, Pil Whan; Ha, Jong Myung.

In: Journal of Clinical Pharmacology, Vol. 46, No. 1, 01.01.2006, p. 109-114.

Research output: Contribution to journalArticle

@article{4174740a01674682a30c6095f71a54e9,
title = "Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe",
abstract = "The authors evaluated the effect of high-dose aspirin at a therapeutic dose, using chlorzoxazone as a probe for CYP2E1 enzyme activity. In a randomized, open-label, 2-way crossover study, 10 healthy men were treated 3 times daily for 6 days with 1 g aspirin or placebo. On day 7, 1 dose of 400 mg chlorzoxazone was administered orally. Plasma concentrations of chlorzoxazone and its metabolite, 6-hydroxychlorzoxazone, were measured. During the aspirin phase, the area under the time-concentration curve (AUC) and peak plasma concentration of chlorzoxazone were 95{\%} (90{\%} confidence interval [CI], 87{\%}-103{\%}) and 90{\%} (90{\%} CI, 80{\%}-101{\%}) of the values during the placebo phase, respectively. High-dose aspirin did not affect the oral clearance of chlorzoxazone significantly (90{\%} CI, 98{\%}-120{\%}; P = .24). The AUC ratio and plasma concentration ratios of 6-hydroxychlorzoxazone/chlorzoxazone were not changed significantly by high-dose aspirin. High-dose aspirin at a therapeutic dose does not affect CYP2E1 activity in humans.",
keywords = "Aspirin, Chlorzoxazone, 6-hydroxychlorzoxazone, Cytochrome P450 2E1 (CYP2E1), Drug interaction",
author = "Ji-Young Park and Kim, {Kyoung Ah} and Park, {Pil Whan} and Ha, {Jong Myung}",
year = "2006",
month = "1",
day = "1",
doi = "10.1177/0091270005282635",
language = "English",
volume = "46",
pages = "109--114",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe

AU - Park, Ji-Young

AU - Kim, Kyoung Ah

AU - Park, Pil Whan

AU - Ha, Jong Myung

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The authors evaluated the effect of high-dose aspirin at a therapeutic dose, using chlorzoxazone as a probe for CYP2E1 enzyme activity. In a randomized, open-label, 2-way crossover study, 10 healthy men were treated 3 times daily for 6 days with 1 g aspirin or placebo. On day 7, 1 dose of 400 mg chlorzoxazone was administered orally. Plasma concentrations of chlorzoxazone and its metabolite, 6-hydroxychlorzoxazone, were measured. During the aspirin phase, the area under the time-concentration curve (AUC) and peak plasma concentration of chlorzoxazone were 95% (90% confidence interval [CI], 87%-103%) and 90% (90% CI, 80%-101%) of the values during the placebo phase, respectively. High-dose aspirin did not affect the oral clearance of chlorzoxazone significantly (90% CI, 98%-120%; P = .24). The AUC ratio and plasma concentration ratios of 6-hydroxychlorzoxazone/chlorzoxazone were not changed significantly by high-dose aspirin. High-dose aspirin at a therapeutic dose does not affect CYP2E1 activity in humans.

AB - The authors evaluated the effect of high-dose aspirin at a therapeutic dose, using chlorzoxazone as a probe for CYP2E1 enzyme activity. In a randomized, open-label, 2-way crossover study, 10 healthy men were treated 3 times daily for 6 days with 1 g aspirin or placebo. On day 7, 1 dose of 400 mg chlorzoxazone was administered orally. Plasma concentrations of chlorzoxazone and its metabolite, 6-hydroxychlorzoxazone, were measured. During the aspirin phase, the area under the time-concentration curve (AUC) and peak plasma concentration of chlorzoxazone were 95% (90% confidence interval [CI], 87%-103%) and 90% (90% CI, 80%-101%) of the values during the placebo phase, respectively. High-dose aspirin did not affect the oral clearance of chlorzoxazone significantly (90% CI, 98%-120%; P = .24). The AUC ratio and plasma concentration ratios of 6-hydroxychlorzoxazone/chlorzoxazone were not changed significantly by high-dose aspirin. High-dose aspirin at a therapeutic dose does not affect CYP2E1 activity in humans.

KW - Aspirin

KW - Chlorzoxazone, 6-hydroxychlorzoxazone

KW - Cytochrome P450 2E1 (CYP2E1)

KW - Drug interaction

UR - http://www.scopus.com/inward/record.url?scp=29644437493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29644437493&partnerID=8YFLogxK

U2 - 10.1177/0091270005282635

DO - 10.1177/0091270005282635

M3 - Article

VL - 46

SP - 109

EP - 114

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -